Cargando…
Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: A prospective cohort study
BACKGROUND: Little is known about the benefits of adjuvant endocrine therapy (ET) in low ER-positive breast cancer (1%–10%) patients. We analyzed the association between ET and breast cancer-specific survival (BCSS) in these patients with respect to the regimen and the duration of ET. METHODS: Patie...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551143/ https://www.ncbi.nlm.nih.gov/pubmed/36209701 http://dx.doi.org/10.1016/j.breast.2022.09.008 |
_version_ | 1784806031870656512 |
---|---|
author | Xie, Yuxin Yang, Libo Wu, Yanqi Zheng, Hong Gou, Qiheng |
author_facet | Xie, Yuxin Yang, Libo Wu, Yanqi Zheng, Hong Gou, Qiheng |
author_sort | Xie, Yuxin |
collection | PubMed |
description | BACKGROUND: Little is known about the benefits of adjuvant endocrine therapy (ET) in low ER-positive breast cancer (1%–10%) patients. We analyzed the association between ET and breast cancer-specific survival (BCSS) in these patients with respect to the regimen and the duration of ET. METHODS: Patients were classified into three groups based on the regimen and duration of ET. The regimens included aromatase inhibitor (AI) monotherapy or sequential tamoxifen followed by an AI (AI/T + AI), or only tamoxifen and no ET. The duration of ET included 2–3 years and >3 years. Multivariate Cox regression analysis was employed to calculate the hazard ratios (HRs) with 95% confidence intervals (CIs). RESULTS: Of the 10,696 patients diagnosed with breast cancer between 2010 and 2020, 407 women were identified with ER-low positive disease and met the inclusion criteria. During a median follow-up of 5.2 years, patients who received ET improved BCSS. Of them, those with AI/T + AI had increased BCSS compared to patients without ET, after adjusting for demographics and tumor characteristics, especially in ER-low/HER-2-positive breast cancer. After additional adjustment for treatment mode, the association maintained a similar trend. Patients who received >3 years of ET was associated with a better DFS. There was no significant difference in BCSS between patients with 2–3 years and >3 years of ET. CONCLUSION: For ER-low patients, findings suggest that ET with AI/T + AI may be a reasonable treatment alternative. This effect should be assessed in randomized studies. |
format | Online Article Text |
id | pubmed-9551143 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-95511432022-10-12 Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: A prospective cohort study Xie, Yuxin Yang, Libo Wu, Yanqi Zheng, Hong Gou, Qiheng Breast Original Article BACKGROUND: Little is known about the benefits of adjuvant endocrine therapy (ET) in low ER-positive breast cancer (1%–10%) patients. We analyzed the association between ET and breast cancer-specific survival (BCSS) in these patients with respect to the regimen and the duration of ET. METHODS: Patients were classified into three groups based on the regimen and duration of ET. The regimens included aromatase inhibitor (AI) monotherapy or sequential tamoxifen followed by an AI (AI/T + AI), or only tamoxifen and no ET. The duration of ET included 2–3 years and >3 years. Multivariate Cox regression analysis was employed to calculate the hazard ratios (HRs) with 95% confidence intervals (CIs). RESULTS: Of the 10,696 patients diagnosed with breast cancer between 2010 and 2020, 407 women were identified with ER-low positive disease and met the inclusion criteria. During a median follow-up of 5.2 years, patients who received ET improved BCSS. Of them, those with AI/T + AI had increased BCSS compared to patients without ET, after adjusting for demographics and tumor characteristics, especially in ER-low/HER-2-positive breast cancer. After additional adjustment for treatment mode, the association maintained a similar trend. Patients who received >3 years of ET was associated with a better DFS. There was no significant difference in BCSS between patients with 2–3 years and >3 years of ET. CONCLUSION: For ER-low patients, findings suggest that ET with AI/T + AI may be a reasonable treatment alternative. This effect should be assessed in randomized studies. Elsevier 2022-09-30 /pmc/articles/PMC9551143/ /pubmed/36209701 http://dx.doi.org/10.1016/j.breast.2022.09.008 Text en © 2022 The Authors. Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Xie, Yuxin Yang, Libo Wu, Yanqi Zheng, Hong Gou, Qiheng Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: A prospective cohort study |
title | Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: A prospective cohort study |
title_full | Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: A prospective cohort study |
title_fullStr | Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: A prospective cohort study |
title_full_unstemmed | Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: A prospective cohort study |
title_short | Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: A prospective cohort study |
title_sort | adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: a prospective cohort study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551143/ https://www.ncbi.nlm.nih.gov/pubmed/36209701 http://dx.doi.org/10.1016/j.breast.2022.09.008 |
work_keys_str_mv | AT xieyuxin adjuvantendocrinetherapyinpatientswithestrogenreceptorlowpositivebreastcanceraprospectivecohortstudy AT yanglibo adjuvantendocrinetherapyinpatientswithestrogenreceptorlowpositivebreastcanceraprospectivecohortstudy AT wuyanqi adjuvantendocrinetherapyinpatientswithestrogenreceptorlowpositivebreastcanceraprospectivecohortstudy AT zhenghong adjuvantendocrinetherapyinpatientswithestrogenreceptorlowpositivebreastcanceraprospectivecohortstudy AT gouqiheng adjuvantendocrinetherapyinpatientswithestrogenreceptorlowpositivebreastcanceraprospectivecohortstudy |